XENE vs ZBIO: fair value comparison
Xenon Pharmaceuticals Inc. and Zenas BioPharma, Inc. Common Stock · Updated 2026-10-19
XENE has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. ZBIO has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, XENE currently ranks higher by quality score.
| XENE | ZBIO | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $33.49 | $24.84 |
| 12-month range | $33.49–$70.96 | $15.20–$43.17 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #276 of 301 Healthcare | #278 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | High |
| Margin trend | Expanding | — |
| Revenue growth | — | Declining |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Downtrend | Mixed |
| 52-week position | The bottom quarter | The lower-middle quarter |
Full single-stock breakdowns: XENE fair value analysis · ZBIO fair value analysis